Meeting
2023 ASCO Annual Meeting
Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study.
Authors
Luca Mastrantoni
Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli–IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
Luca Mastrantoni , Giovanna Garufi , Noemi Maliziola , Elena Di Monte , Giorgia Arcuri , Valentina Frescura , Angelachiara Rotondi , Giulia Giordano , Luisa Carbognin , Alessandra Fabi , Ida Paris , Fabio Marazzi , Franco Antonio , Gianluca Franceschini , Armando Orlandi , Antonella Palazzo , Giovanni Scambia , Giampaolo Tortora , Emilio Bria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 597)
DOI
10.1200/JCO.2023.41.16_suppl.597
Abstract #
597
Poster Bd #
427
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).
First Author: Ji-Jung Jung
Poster
2012 ASCO Annual Meeting
Topoisomerase II alpha gene status, HER2, and microtubule-associated protein tau as predictors of pathologic complete response after neoadjuvant chemotherapy.
First Author: Agust Barnadas
First Author: Jose Pacheco
Poster
2022 ASCO Annual Meeting
The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.
First Author: Lorenza Mittempergher